arrow_back Civic Audit
Share share

SAFE Drugs Act of 2026: New Regulations for Compounding Pharmacies

This act strengthens oversight of custom-made drugs to ensure they are not just mass-produced copies of existing medicines. It aims to protect patients by requiring stricter inspections and reporting for facilities that make drugs in large quantities.
Key points
Limits pharmacies from making more than 20 copies of commercially available drugs per month.
Requires pharmacies to report drugs sent to patients living in different states.
Mandates safety inspections for large-scale drug facilities before they start operating and every two years thereafter.
Adjusts registration fees to better fund government activities that ensure drug safety.
article Official text account_balance Process page notifications_active Track this Bill
Status: Introduced
Civic Will
Checking votes...
I support
I oppose
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 119_S_3794
Sponsor: Sen. Banks, Jim [R-IN]
Process start date: 2026-02-05
System Note: Lustra is free, publicly auditable civic infrastructure — full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source—always verify them if you can.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

SAFE Drugs Act of 2026

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_3794.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2026-02-05.

What are the main provisions?

Key points include:

  • Limits pharmacies from making more than 20 copies of commercially available drugs per month.
  • Requires pharmacies to report drugs sent to patients living in different states.
  • Mandates safety inspections for large-scale drug facilities before they start operating and every two years thereafter.
  • Adjusts registration fees to better fund government activities that ensure drug safety.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Banks, Jim [R-IN].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-02-21.

What is the impact of this bill?

We don't know—that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health